Overview

Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

Status:
Terminated
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell
Phase:
Phase 2
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Mitoxantrone